Related Experiment Video
Updated: Jan 13, 2026

Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
Published on: October 31, 2025
Promising Treatments in Juvenile Dermatomyositis
Belina Y Yi1, Mercy Joyce2, Ross Gilbert3
1Division of Pediatric Allergy, Immunology, and Rheumatology, Department of Pediatrics, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Blalock 430, Baltimore, MD 21287, USA.
None:
Juvenile dermatomyositis (JDM) is an autoimmune systemic connective tissue disorder treated by various anti-inflammatory and immunomodulating agents. JDM typically requires immunomodulatory therapies including corticosteroids, disease-modifying antirheumatic drugs, intravenous immunoglobulins, and other steroid-sparing therapies. It is important to also employ nonpharmacologic interventions, which are integral in the treatment of JDM to optimize outcomes. These include photoprotection, physical therapy, occupational therapy, and mental health support. There are increasing number of exciting, emerging therapies including as Janus kinase-inhibitors, CAR-T cells, and interferon blockers. This review will provide summary of current JDM treatments and some promising newly emerging therapies.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Myocarditis III: Medical Management
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
